Drugs for Porphyria (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 110)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Lidocaine |
Approved, Vet_approved |
Phase 4 |
|
137-58-6 |
3676 |
Synonyms:
.alpha.-(Diethylamino)-2,6-acetoxylidide
.alpha.-Diethylamino-2,6-dimethylacetanilide
.alpha.-Diethylaminoaceto-2,6-xylidide
.omega.-Diethylamino-2,6-dimethylacetanilide
137-58-6
2-(diethylamino)-2',6'-Acetoxylidide
2-(Diethylamino)-2',6'-acetoxylidide
2-(diethylamino)-N-(2,6-Dimethylphenyl)acetamide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
2-2ETN-2MePhAcN
2-Diethylamino-N-(2,6-dimethylphenyl)acetamide
2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide
4-12-00-02538 (Beilstein Handbook Reference)
6108-05-0 (MONOHYDROCHLORIDE MONOHYDRATE))
6108-05-0 (mono-hydrochloride, mono-hydrate)
73-78-9 (mono-hydrochloride)
AB00053581
AC-10282
AC1L1GGQ
AC1Q2Z7J
a-diethylamino-2,6-Dimethylacetanilide
After Burn Double Strength Gel
After Burn Double Strength Spray
After Burn Gel
After Burn Spray
AKOS001026768
alfa-Dietilamino-2,6-dimetilacetanilide
alfa-Dietilamino-2,6-dimetilacetanilide [Italian]
Alphacaine
alpha-diethylamino-2,6-dimethylacetanilide
alpha-diethylamino-2,6-Dimethylacetanilide
alpha-Diethylamino-2,6-dimethylacetanilide
Anestacon
Anestacon Jelly
ARONIS23855
Astrazeneca brand OF lidocaine
BIDD:GT0342
Bio-0767
Bio1_000379
Bio1_000868
Bio1_001357
Bio2_000079
Bio2_000559
BPBio1_000197
BRD-K52662033-001-02-6
BRD-K52662033-003-05-5
BRN 2215784
BSPBio_000179
BSPBio_001359
BSPBio_003004
C07073
C14H22N2O
Cappicaine
CAS-73-78-9
CDS1_000283
CHEBI:6456
CHEMBL79
CID3676
Cito optadren
CPD000058189
Cuivasil
D00358
Dalcaine
DB00281
Dentipatch
Dentipatch (TN)
DermaFlex
Diethylaminoaceto-2,6-xylidide
Dilocaine
DivK1c_000174
DivK1c_001323
Duncaine
EINECS 205-302-8
ELA-Max
EMBOLEX
Emla Cream
Esracaine
FT-0082378
Gravocain
HMS1791D21
HMS1989D21
HMS2051C21
HMS2089E15
HMS548M19
HSDB 3350
I01-2704
IDI1_000174
IDI1_033829
Isicaina
Isicaine
Jenapharm brand OF lidocanine hydrochloride
Jetocaine
KBio1_000174
KBio2_000079
KBio2_001598
KBio2_002647
KBio2_004166
KBio2_005215
KBio2_006734
KBio3_000157
KBio3_000158
KBio3_002224
KBioGR_000079
KBioGR_000599
KBioSS_000079
KBioSS_001598
L0156
L1026_SIGMA
L7757_SIGMA
Lanabiotic
L-Caine
Leostesin
|
Lida-Mantle
Lidocaina
Lidocaína
Lidocaina [INN-Spanish]
lidocaine
Lidocaine
LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE)
Lidocaine (JP15/USP/INN)
Lidocaine (VAN)
Lidocaine [USAN:INN:JAN]
Lidocaine carbonate
Lidocaine Carbonate
Lidocaine carbonate (2:1)
Lidocaine hydrocarbonate
Lidocaine Hydrocarbonate
Lidocaine hydrochloride
Lidocaine monoacetate
Lidocaine monohydrochloride
Lidocaine Monohydrochloride
Lidocaine monohydrochloride, monohydrate
Lidocaine sulfate (1:1)
Lidocainum
Lidocainum [INN-Latin]
Lidocaton
Lidoderm
Lidoject-1
Lidoject-2
LIDOPEN
Lignocaine
Lignocainum
Lingocaine
Lopac0_000669
Lopac-L-5647
LQZ
LS-805
Maricaine
Maybridge1_002571
MLS000069724
MLS000758263
MLS001074177
MolPort-001-783-478
N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide
N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide
NCGC00015611-01
NCGC00015611-02
NCGC00015611-03
NCGC00015611-04
NCGC00015611-14
NCGC00022176-05
NCGC00022176-06
NCGC00022176-07
NCGC00022176-08
NCGC00022176-09
nchembio.65-comp16
NINDS_000174
Norwood Sunburn Spray
Novocol brand OF lidocaine hydrochloride
NSC 40030
NSC40030
Octocaine
Octocaine-100
Octocaine-50
Prestwick0_000050
Prestwick1_000050
Prestwick2_000050
Prestwick3_000050
Remicaine
Rocephin Kit
Rucaina
S1357_Selleck
SAM001247018
SMR000058189
Solarcaine aloe extra burn relief cream
Solcain
SPBio_001525
SPBio_002100
Spectrum_001118
Spectrum2_001343
Spectrum3_001392
Spectrum4_000070
Spectrum5_001549
STK552033
Strathmann brand OF lidocaine hydrochloride
UNII-98PI200987
WLN: 2N2 & 1VMR B1 F1
Xilina
Xilocaina
Xilocaina [Italian]
Xllina
Xycaine
Xylestesin
Xylesthesin
Xylocain
Xylocaine
Xylocaine (TN)
Xylocaine 5% Spinal
Xylocaine CO2
Xylocaine Dental Ointment
Xylocaine Endotracheal
Xylocaine Test Dose
Xylocaine Viscous
Xylocaine-Mpf
Xylocaine-Mpf with Glucose
Xylocard
Xylocitin
Xyloneural
Xyloneural (free base)
Xylotox
Zilactin-L
Zingo
α-diethylamino-2,6-dimethylacetanilide
|
|
2 |
|
Prednisone |
Approved, Vet_approved |
Phase 4 |
|
53-03-2 |
5865 |
Synonyms:
(1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione
(8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione
(8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione
.delta. E
.delta.(sup1)-Cortisone
.delta.1-Cortisone
.delta.1-Dehydrocortisone
.delta.-Cortelan
.delta.-Cortisone
.delta.-Cortone
.delta.-E
.delta.sone
1,2-Dehydrocortisone
1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione
1,4-Pregnadiene-17a,21-diol-3,11,20-trione
1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17α,21-diol-3,11,20-trione
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione
1-Cortisone
1-Dehydrocortisone
53-03-2
68-59-7
81552_FLUKA
AC-11112
AC1L1LB2
AC1Q29EZ
Acis brand OF prednisone
ACon0_000082
ACon1_000297
Adasone
AI3-52939
Ancortone
apo-Prednisone
Apo-prednisone
Apo-Prednisone
Apotex brand OF prednisone
Aventis brand OF prednisone
Betapar
Bicortone
Bio-0649
BPBio1_000323
BRD-K85883481-001-04-2
BSPBio_000293
C07370
C21H26O5
Cartancyl
CCRIS 2646
CHEBI:8382
CHEMBL635
CID5865
Colisone
Cortan
Cortancyl
Cortidelt
Cotone
CPD001227202
Cutason
Dacorten
Dacortin
DB00635
Decortancyl
Decortin
Decortisyl
Dehydrocortisone
Dekortin
Delcortin
Dellacort
Dellacort A
delta cortelan
Delta Cortelan
Delta E
Delta E.
delta(sup 1)-Cortisone
delta(sup 1)-Dehydrocortisone
delta-1-Cortisone
delta-1-Dehydrocortisone
Delta-cortelan
Delta-Cortelan
Deltacortene
delta-Cortisone
Deltacortisone
Delta-cortisone
delta-Cortone
Deltacortone
Delta-cortone
Delta-dome
Delta-Dome
Deltasone
Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone
Deltison
Deltisona
Deltisone
Deltra
Diadreson
Di-Adreson
Diba brand OF prednisone
Econosone
EINECS 200-160-3
Encorton
Encortone
Enkortolon
Enkorton
Fawns and mcallan brand OF prednisone
Fernisone
Ferring brand OF prednisone
Fiasone
GALENpharma brand OF prednisone
Halsey drug brand OF prednisone
Hexal brand OF prednisone
HMS1568O15
HMS2090J13
|
Hoechst brand OF prednisone
Hostacortin
HSDB 3168
ICN brand OF prednisone
Incocortyl
In-Sone
Juvason
Kortancyl
Lichtenstein brand OF prednisone
Liquid pred
Liquid Pred
Lisacort
LMST02030180
Lodotra
LS-1325
MEGxm0_000443
Me-Korti
Merck brand OF prednisone
Merz brand OF prednisone
Metacortandracin
Meticorten
Meticorten (Veterinary)
Metrevet (Veterinary)
Mibe brand OF prednisone
MLS001061265
MLS001304073
MLS001335907
MLS001335908
MLS002154191
MLS002207083
MolPort-001-740-041
NCGC00090766-01
NCGC00090766-02
NCGC00090766-03
NCI60_000008
NCI-C04897
Nisona
Nizon
Novoprednisone
NSC 10023
NSC10023
Nurison
Orasone
Origen Prednisone
P1276
P6254_SIGMA
Panafcort
Panasol
Paracort
Parmenison
Pehacort
Pharmacia brand OF prednisone
PRD
Precort
Predeltin
Predni tablinen
Prednicen-M
Prednicorm
Prednicort
Prednicot
Prednidib
Prednilonga
Predniment
Prednison
Prednison acsis
Prednison galen
Prednison hexal
Prednisona
Prednisona [INN-Spanish]
Prednisone
Prednisone [INN:BAN]
Prednisone Intensol
Prednisonum
Prednisonum [INN-Latin]
Prednitone
Prednizon
Prednovister
Presone
Prestwick_405
Prestwick0_000077
Prestwick1_000077
Prestwick2_000077
Prestwick3_000077
Pronison
Pronisone
Rectodelt
Retrocortine
S1622_Selleck
SAM002264641
Schering-plough brand OF prednisone
Seatrace brand OF prednisone
Servisone
SK-Prednisone
SMR000718760
SMR001227202
Solvay brand OF prednisone
Sone
SPBio_002214
Sterapred
Supercortil
Trommsdorff brand OF prednisone
U 6020
Ultracorten
Ultracortene
UNII-VB0R961HZT
Winpred
WLN: L E5 B666 CV OV AHTTT&J A1 E1 FV1Q FQ
Wojtab
Zenadrid
Zenadrid (veterinary)
Zenadrid [veterinary]
ZINC03875357
|
|
3 |
|
chloroquine |
Approved, Investigational, Vet_approved |
Phase 4 |
|
54-05-7 |
2719 |
Synonyms:
( -)-Chloroquine
(-)-Chloroquine
(+)-Chloroquine
(R)-(-)-Chloroquine
{4-[(7-chloroquinolin-4-yl)amino]pentyl}diethylamine
3377 RP opalate
3545-67-3
50-63-5
54-05-7
56598-66-4
58175-86-3
58175-87-4
7-Chloro-4-((4-(diethylamino)-1-methylbutyl)amino)quinoline
7-Chloro-4-[[4-(diethylamino)-1-methylbutyl]amino]quinoline
AB00053436
AC1L1EB8
AC1Q2ZA7
AC1Q2ZA8
Amokin
Aralen
Aralen HCl
Arechin
Arechine
Arequin
Arolen
Arthrochin
Artrichin
Avlochlor
Avloclor
Bemaco
Bemaphate
Bemaphic acid
Bemasulph
Benaquin
Bipiquin
BPBio1_000655
BRD-A91699651-065-01-1
BRN 0482809
BSPBio_000595
BSPBio_002001
C07625
C18H26ClN3
Capquin
CCRIS 3439
CHEBI:3638
CHEMBL76
Chemochin
Chingamin
Chloraquine
Chlorochin
Chlorochine
Chlorochinum
Chloroin
Chloroquin
Chloroquina
chloroquine
Chloroquine
Chloroquine (USP/INN)
Chloroquine (VAN)
Chloroquine [USAN:INN:BAN]
Chloroquine Bis-Phosphoric Acid
Chloroquine phosphate
Chloroquine Phosphate
Chloroquine sulfate
Chloroquine sulphate
Chloroquinium
Chloroquinum
Chloroquinum [INN-Latin]
Chlorquin
CID2719
Cidanchin
Clorochina
Clorochina [DCIT]
Cloroquina
Cloroquina [INN-Spanish]
Cocartrit
CQ
CU-01000012392-2
D02366
Dawaquin
DB00608
Delagil
Dichinalex
DivK1c_000404
EINECS 200-191-2
Elestol
Gontochin
Gontochin phosphate
Heliopar
HMS2090O03
HSDB 3029
Hydroxychloroquine Sulfate
IDI1_000404
Imagon
|
Ipsen 225
Iroquine
KBio1_000404
KBio2_000592
KBio2_003160
KBio2_005728
KBio3_001221
KBioGR_000778
KBioSS_000592
Khingamin
Klorokin
Lapaquin
Lopac0_000296
LS-141726
Malaquin
Malaquin (*Diphosphate*)
Malaren
Malarex
Mesylith
Miniquine
MolMap_000009
MolPort-001-783-623
N(4)-(7-chloro-4-Quinolinyl)-N(1),N(1)-diethyl-1,4-pentanediamine
N4-(7-chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine
N4-(7-Chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine
N4-(7-chloroquinolin-4-yl)-N1,N1-diethylpentane-1,4-diamine
NCGC00015256-04
NCGC00162120-01
nchembio.215-comp4
nchembio.368-comp8
nchembio.87-comp17
NCI60_000894
Neochin
NINDS_000404
Nivachine
Nivaquine
Nivaquine b
Nivaquine B
NSC 187208
NSC14050
NSC187208
Pfizerquine
Plaquenil
Prestwick0_000548
Prestwick1_000548
Prestwick2_000548
Prestwick3_000548
Quinachlor
Quinagamin
Quinagamine
Quinercyl
Quingamine
Quinilon
Quinoscan
Resochen
Resochin
Resoquina
Resoquine
Reumachlor
Reumaquin
Rivoquine
Ro 01-6014/N2
Ronaquine
Roquine
RP 3377
RP-3377
Sanoquin
Silbesan
Siragan
SMP2_000034
SN 6718
SN-7618
Solprina
Sopaquin
SPBio_000174
SPBio_002516
Spectrum_000132
Spectrum2_000127
Spectrum3_000341
Spectrum4_000279
Spectrum5_000707
ST 21
ST 21 (pharmaceutical)
Sulfate, chloroquine
Sulphate, chloroquine
Tanakan
Tanakene
Tresochin
Trochin
UNII-886U3H6UFF
W 7618
WIN 244
WLN: T66 BNJ EMY1&3N2&2 IG
|
|
4 |
|
Azathioprine |
Approved |
Phase 4 |
|
446-86-6 |
2265 |
Synonyms:
[Methyl(nitroimidazolyl)mercaptopurine]
446-86-6
55774-33-9 (hydrochloride salt)
6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-1H-purine
6-((1-Methyl-4-nitroimidazol-5-yl)thio)purine
6-({4-nitro-1-methyl-1H-imidazol-5-yl}sulfanyl)-7H-purine
6-(1'-Methyl-4'-nitro-5'-imidazolyl)mercaptopurine
6-(1'-Methyl-4'-nitro-5'-imidazolyl)-mercaptopurine
6-(1-Methyl-4-nitroimidazol-5-yl)thiopurine
6-(1-Methyl-4-nitroimidazol-5-ylthio)purin
6-(1-Methyl-4-nitroimidazol-5-ylthio)purin [Czech]
6-(1-Methyl-p-nitro-5-imidazolyl)thiopurine
6-(1-Methyl-p-nitro-5-imidazolyl)-thiopurine
6-(3-Methyl-5-nitro-3H-imidazol-4-ylsulfanyl)-7H-purine
6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purine
6-(Methyl-p-nitro-5-imidazolyl)thiopurine
6-(Methyl-p-nitro-5-imidazolyl)-thiopurine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-7H-purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-Purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-7H-purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-9H-purine
6-[(1-Methyl-4-nitroimidazol-5-yl)- thio] purine
6-[(1-Methyl-4-nitroimidazol-5-yl)thio]purine
6-1'-Methyl,4'-nitro,5'-imidazolyl mercaptopurine
A 4638
A2593_SIAL
A4638_SIAL
A4638_SIGMA
AB00443544
AB00443544-03
AC1L1DAL
AC1Q3Z1F
AC-4230
AI3-50290
AI-981/34845012
Azamun
Azamun [Czech]
Azanin
Azasan
Azasan (TN)
Azasan, Imuran, Azamun, BW-57-322, NSC-39084, Azathioprine
Azathioprin
azathioprine
Azathioprine
Azathioprine (JP15/USP/INN)
Azathioprine [USAN:INN:BAN:JAN]
Azathioprine sodium
Azathioprine Sodium
Azathioprine sodium salt
Azathioprine sulfate
Azathioprinum
Azathioprinum [INN-Latin]
Azathiopurine
azatiopr in
Azatioprin
Azatioprina
Azatioprina [INN-Spanish]
Azothioprine
B. W. 57-322
BPBio1_000054
BRD-K32821942-001-05-6
BRD-K60324116-001-01-5
BSPBio_000048
BSPBio_001876
BW 57322
BW 57-322
BW-57-322
C06837
C9H7N7O2S
CAS-446-86-6
CBDivE_013132
CCRIS 62
Ccucol
CHEBI:2948
CHEMBL1542
ChemDiv1_002659
CID2265
cMAP_000046
CPD000427366
Cytostatics
D00238
DB00993
DivK1c_000586
|
EINECS 207-175-4
EU-0100027
FT-0083532
HMS1568C10
HMS1920E17
HMS2091K19
HMS501N08
HMS594I19
HSDB 7084
IDI1_000586
Immuran
Imuran
Imuran (TN)
Imurek
Imurel
KBio1_000586
KBio2_000464
KBio2_002427
KBio2_003032
KBio2_004995
KBio2_005600
KBio2_007563
KBio3_001376
KBio3_002906
KBioGR_000646
KBioGR_002427
KBioSS_000464
KBioSS_002433
Lopac0_000027
Lopac-A-4638
LS-123
Methylnitroimidazolylmercaptopurine
MLS001049307
MolPort-000-745-914
MolPort-000-764-262
MolPort-003-665-485
Muran
NCGC00015060-01
NCGC00015060-02
NCGC00015060-04
NCGC00015060-12
NCGC00090836-01
NCGC00090836-02
NCGC00090836-03
NCGC00090836-04
NCGC00090836-05
NCGC00090836-06
NCGC00094593-01
NCGC00094593-02
NCGC00094593-03
NCI-C03474
NINDS_000586
NSC 39084
NSC39084
NSC-39084
Oprea1_375441
Oprea1_533384
Oprea1_633462
Prestwick_41
Prestwick0_000094
Prestwick1_000094
Prestwick2_000094
Prestwick3_000094
S1721_Selleck
SAM002589938
SDCCGMLS-0065415.P001
SMR000427366
Sodium, azathioprine
SPBio_000255
SPBio_001987
Spectrum_000064
SPECTRUM1500133
Spectrum2_000068
Spectrum3_000308
Spectrum4_000243
Spectrum5_000848
STK831906
STOCK1S-20293
STOCK1S-27186
Thiopurine 6-(1-methyl-4-nitroimidazol-5-yl)
UNII-MRK240IY2L
WLN: T56 BM DN FN HNJ IS- ET5N CNJ A1 DNW
ZINC04258316
|
|
5 |
|
Propofol |
Approved, Investigational, Vet_approved |
Phase 4 |
|
2078-54-8 |
4943 |
Synonyms:
2, 6-Diisopropylphenol
2,6 Diisopropylphenol
2,6-bis(1-methylethyl)phenol
2,6-bis(1-methylethyl)-phenol
2,6-Bis(1-methylethyl)phenol
2,6-Bis(Isopropyl)-phenol
2,6-di(propan-2-yl)phenol
2,6-Diisopropyl phenol
2,6-Diisopropylphenol
2,6-DIISOPROPYLPHENOL
2078-54-8
28449-97-0
4-06-00-03435 (Beilstein Handbook Reference)
50356-15-5
AB00513968
Abbott brand OF propofol
Abbott Brand of Propofol
AC1L1J9Y
AC1Q1OUI
AC-2038
AI3-26295
Alpha Brand of Propofol
Alpha Brand OF propofol
AM-149
Ampofol
Aquafol
Astra brand OF propofol
Astra Brand of Propofol
AstraZeneca brand OF propofol
AstraZeneca Brand of Propofol
BIDD:GT0436
Biomol-NT_000248
BPBio1_000950
BPBio1_000969
Braun brand OF propofol
Braun Brand of Propofol
BRD-K82255054-001-03-5
BRN 1866484
BSPBio_000862
C07523
C12H18O
CAS-2078-54-8
CCRIS 9000
CHEBI:44915
CHEMBL526
CID4943
CPD000059151
CPD-11437
Curamed brand OF propofol
Curamed Brand of Propofol
D00549
D015742
D0617
D126608
D126608_ALDRICH
DB00818
DDS-04F
Diisopropylphenol
Dipravan
Diprivan
Diprivan (TN)
Diprivan Injectable emulsion
Disoprivan
Disoprofol
EINECS 218-206-6
EU-0100437
Fresenius brand OF propofol
Fresenius Brand of Propofol
Fresenius kabi brand OF propofol
Fresenius Kabi Brand of Propofol
Fresofol
ghl.PD_Mitscher_leg0.558
HMS1570L04
HMS2089O21
HMS2094E17
HSDB 7123
|
ICI 35,868
ICI 35868
ICI35,868
ICI-35,868
ICI35868
ICI-35868
InChI=1/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H
Ivofol
Jsp004266
Juste brand OF propofol
Juste Brand of Propofol
Lopac0_000437
Lopac-D126608
LS-996
MLS001066348
MLS001335999
MLS002454360
MolPort-001-794-517
NCGC00015389-01
NCGC00015389-02
NCGC00015389-04
NCGC00015389-09
NCGC00091538-01
NCGC00091538-02
NCGC00091538-03
NCGC00091538-04
NCGC00091538-05
NCGC00091538-06
nchembio.552-comp7
NSC 5105
NSC5105
Parnell brand OF propofol
Parnell Brand of Propofol
PFL
Pisa brand OF propofol
Pisa Brand of Propofol
Prestwick0_000931
Prestwick1_000931
Prestwick2_000931
Prestwick3_000931
propofol
Propofol
Propofol (JAN/USAN/INN)
Propofol [USAN:INN:BAN]
Propofol abbott
Propofol Abbott
Propofol fresenius
Propofol Fresenius
Propofol IDD-D
Propofol MCT
Propofol rovi
Propofol Rovi
Propofol(2,6-Diisopropylphenol)
Propofol-lipuro
Propofol-Lipuro
Propofolum
Propofolum [Latin]
Rapinovet
Recofol
Rovi brand OF propofol
Rovi Brand of Propofol
S01-0189
SAM002264610
Schering brand OF propofol
Schering Brand of Propofol
SMR000059151
SPBio_003031
SPECTRUM1505022
ST50405911
UNII-YI7VU623SF
W505102_ALDRICH
ZD-0859
Zeneca brand OF propofol
Zeneca Brand of Propofol
ZINC00968303
|
|
6 |
|
Ketamine |
Approved, Vet_approved |
Phase 4 |
|
6740-88-1 |
3821 |
Synonyms:
(-)-Ketamine
(+-)-Ketamine
(+/-)-2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone
(+/-)-2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone
(+/-)-Ketamine
(±)-ketamine
(S)-(-)-Ketamine
(S)-Ketamine
100477-72-3
2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one
2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone
2-(2-chloro-Phenyl)-2-methylamino-cyclohexanone
2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone
2-(methylamino)-2-(2-chlorophenyl)cyclohexanone
2-(methylamino)-2-(2-Chlorophenyl)cyclohexanone
2-(Methylamino)-2-(2-chlorophenyl)cyclohexanone
2-(o-chlorophenyl)-2-(methylamino)-cyclohexanone
2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone
2-(o-Chlorophenyl)-2-(methylamino)-cyclohexanone
2-(O-Chlorophenyl)-2-(methylamino)-cyclohexanone
33643-45-7
6740-88-1
79499-51-7
AC1L1GSH
AC1Q40UR
AKOS001053247
BRN 2216965
C07525
C13H16ClNO
Calipsol
Calypsol
Cetamina
Cetamina [INN-Spanish]
CHEBI:138833
CHEBI:6121
CHEMBL742
CI 581 base
CI-581
CID3821
CLSTA 20
Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)- (9CI)
Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (+-)- (9CI)
Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, (+/-)- (8CI)
D08098
DB01221
DEA No. 7285
DivK1c_000217
|
dl-Ketamine
DL-ketamine
DL-Ketamine
EINECS 229-804-1
Esketamine
Green
IDI1_000217
Kalipsol
KBio1_000217
Ketaject
Ketalar
Ketalar base
Ketamina
ketamine
Ketamine
Kétamine
Ketamine (INN)
Ketamine [INN:BAN]
Ketamine base
Ketamine Base
Ketamine HCL
KETAMINE HCL
Ketamine hydrochloride
Ketaminum
Ketaminum [INN-Latin]
Ketanest
Ketaset
Ketoject
Ketolar
l-Ketamine
L-Ketamine
LS-57301
MLS001331674
MolPort-001-838-070
NCGC00159480-02
NCGC00159480-03
NINDS_000217
NMDA
NSC 70151
NSC70151
SMR000238141
Special K
Special K [street name]
T385
Tekam
Tekam (TN)
UNII-690G0D6V8H
|
|
7 |
|
Hormone Antagonists |
|
Phase 4 |
|
|
|
8 |
|
Hormones |
|
Phase 4 |
|
|
|
9 |
|
Antimetabolites |
|
Phase 4 |
|
|
|
10 |
|
Pharmaceutical Solutions |
|
Phase 4 |
|
|
|
11 |
|
Anesthetics |
|
Phase 4 |
|
|
|
12 |
|
glucocorticoids |
|
Phase 4 |
|
|
|
13 |
|
Anti-Inflammatory Agents |
|
Phase 4 |
|
|
|
14 |
|
Immunologic Factors |
|
Phase 4 |
|
|
|
15 |
|
Antineoplastic Agents, Hormonal |
|
Phase 4 |
|
|
|
16 |
|
Anthelmintics |
|
Phase 4 |
|
|
|
17 |
|
Amebicides |
|
Phase 4 |
|
|
|
18 |
|
Chloroquine diphosphate |
|
Phase 4 |
|
50-63-5 |
|
19 |
|
Immunosuppressive Agents |
|
Phase 4 |
|
|
|
20 |
|
Analgesics, Non-Narcotic |
|
Phase 4 |
|
|
|
21 |
|
Analgesics |
|
Phase 4 |
|
|
|
22 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 4 |
|
|
|
23 |
|
Hypnotics and Sedatives |
|
Phase 4 |
|
|
|
24 |
|
Anesthetics, General |
|
Phase 4 |
|
|
|
25 |
|
Anesthetics, Intravenous |
|
Phase 4 |
|
|
|
26 |
|
Deferasirox |
Approved, Investigational |
Phase 3 |
|
201530-41-8 |
5493381 |
Synonyms:
deferasirox
Deferasirox
Deferasiroxum
Deferasiroxum [inn-latin]
|
|
|
27 |
|
Colestipol |
Approved |
Phase 2, Phase 3 |
|
26658-42-4 |
|
Synonyms:
|
Copolymer of bis(2-aminoethyl)amine and 2-(chloromethyl)oxirane
Epichlorohydrin-tetraethylenepentamine polymer
|
|
28 |
|
Hydroxychloroquine |
Approved |
Phase 3 |
|
118-42-3 |
3652 |
Synonyms:
(+-)-Hydroxychloroquine
(±)-hydroxychloroquine
118-42-3
2-((4-((7-chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol
2-((4-((7-chloro-4-Quinolyl)amino)pentyl)ethylamino)ethanol
2-((4-((7-Chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol
2-(N-(4-(7-chlor-4-chinolylamino)-4-methylbutyl)ethylamino)ethanol
2-(N-(4-(7-Chlor-4-chinolylamino)-4-methylbutyl)ethylamino)ethanol
2-[{4-[(7-chloroquinolin-4-yl)amino]pentyl}(ethyl)amino]ethanol
2-[4-[(7-chloroquinolin-4-yl)amino]pentyl-ethylamino]ethanol
5-22-10-00280 (Beilstein Handbook Reference)
747-36-4 (sulfate (1:1) salt)
7-chloro-4-(4-(ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline
7-chloro-4-(4-(Ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline
7-Chloro-4-(4-(ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline
7-chloro-4-(4-(N-Ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino)quinoline
7-Chloro-4-(4-(N-ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino)quinoline
7-chloro-4-(4-(N-Ethyl-N-b-hydroxyethylamino)-1-methylbutylamino)quinoline
7-chloro-4-(4-(N-ethyl-N-β-hydroxyethylamino)-1-methylbutylamino)quinoline
7-chloro-4-(4-(N-Ethyl-N-β-hydroxyethylamino)-1-methylbutylamino)quinoline
7-Chloro-4-(5-(N-ethyl-N-2-hydroxyethylamino)-2-pentyl)aminoquinoline
7-chloro-4-[4-(N-Ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino]quinoline
7-chloro-4-[4-(N-Ethyl-N-b-hydroxyethylamino)-1-methylbutylamino]quinoline
7-chloro-4-[4-(N-ethyl-N-β-hydroxyethylamino)-1-methylbutylamino]quinoline
7-chloro-4-[4-(N-Ethyl-N-β-hydroxyethylamino)-1-methylbutylamino]quinoline
7-chloro-4-[5-(N-ethyl-N-2-hydroxyethylamino)-2-pentyl]aminoquinoline
7-chloro-4-[5-(N-Ethyl-N-2-hydroxyethylamino)-2-pentyl]aminoquinoline
AC1L1GEW
Axemal
BRN 0253894
C07043
C18H26ClN3O
CHEMBL1535
CID3652
D08050
DB01611
DivK1c_000942
Dolquine
EINECS 204-249-8
Ercoquin
Gen-Hydroxychloroquine 200mg Tablets
HCQ
|
Hidroxicloroquina
Hidroxicloroquina [inn-spanish]
Hidroxicloroquina [INN-Spanish]
HMS502P04
Hydroxychlorochin
Hydroxychloroguine
hydroxychloroquine
Hydroxychloroquine
Hydroxychloroquine (INN)
Hydroxychloroquine [INN:BAN]
Hydroxychloroquine sulfate
Hydroxychloroquine sulfate (1:1) salt
Hydroxychloroquine Sulfate (1:1) Salt
Hydroxychloroquinum
Hydroxychloroquinum [inn-latin]
Hydroxychloroquinum [INN-Latin]
IDI1_000942
Idrossiclorochina
Idrossiclorochina [dcit]
Idrossiclorochina [DCIT]
KBio1_000942
LS-66614
MolPort-003-847-792
NCGC00159483-02
NINDS_000942
NSC4375
Oxichlorochine
Oxichlorochinum
Oxichloroquine
Oxychlorochin
Oxychloroquine
PlaqueN/A
Plaquenil
Polirreumin
Polirreumin (TN)
Quensyl
SPBio_001116
Spectrum2_001238
Spectrum5_001697
ST072188
UNII-4QWG6N8QKH
WIN 1258
|
|
29 |
|
Azithromycin |
Approved |
Phase 3 |
|
83905-01-5 |
447043 55185 |
Synonyms:
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-13-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-b-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-11-{[3,4,6-trideoxy-3-(dimethylamino)-b-D-xylo-hexopyranosyl]oxy}-1-oxa-6-azacyclopentadecan-13-yl 2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranoside
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-11-{[3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl]oxy}-1-oxa-6-azacyclopentadecan-13-yl 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranoside
121470-24-4
1-Oxa-6-azacyclopentadecan-15-one, 13-((2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)-,(2R-(2R*,3S*
75199_FLUKA
83905-01-5
9-Deoxo-9a-aza-9a-methyl-9a-homoerythromycin A
AC-16014
AC1L9KEG
Aritromicina
Azadose
Azasite
Azenil
Azifast
Azigram
Azimakrol
Azithramycine
azithromycin
Azithromycin
Azithromycin & Tumor Necrosis Factor
Azithromycin (AIDS Initiative)
Azithromycin (anhydrous)
Azithromycin dihydrate
Azithromycin monohydrate
Azithromycin Monohydrate
Azithromycin pfizer brand
Azithromycine
Azithromycinum
Azitrocin
Azitromax
Azitromicina
Azitromin
Azythromycin
Bayer brand OF azithromycin dihydrate
BIDD:GT0792
Bio-0676
BRN 5387583
BSPBio_002285
C38H72N2O12
CCRIS 1961
CHEBI:2955
CHEMBL529
CID447043
CP62,993
CP-62993
CPD000471864
DCH3
Dihydrate, azithromycin
DivK1c_000233
DRG-0104
Funk brand OF azithromycin dihydrate
Goxal
Hemomycin
HMS1922G12
|
HMS2094M11
HMS500L15
HSDB 7205
IDI1_000233
KBio1_000233
KBio2_000787
KBio2_003355
KBio2_005923
KBio3_001505
KBioGR_000731
KBioSS_000787
Lesvi brand OF azithromycin dihydrate
LS-1834
Mack brand OF azithromycin dihydrate
Misultina
MLS001055353
MLS001066331
MLS001201763
MLS001304005
MLS001332499
MLS001332500
MolPort-002-507-426
Monohydrate, azithromycin
NCGC00090753-01
NCGC00090753-02
NINDS_000233
NSC643732
Pfizer brand OF azithromycin
Pfizer brand OF azithromycin dihydrate
Pharmacia brand OF azithromycin dihydrate
SAM002589961
SMR000471864
SPBio_001544
Spectrum_000307
SPECTRUM1503679
Spectrum2_001582
Spectrum3_000653
Spectrum4_000186
Spectrum5_001867
Sumamed
Toraseptol
Tromix
Ultreon
UNII-JTE4MNN1MD
Vinzam
Vita brand OF azithromycin dihydrate
XZ-450
Zentavion
ZIT
Zithromac
Zithromax
Zithromax IV
Zithromycin
Zitromax
Zitromax Avium 600
Zmas
Zmax
Z-Pak
|
|
30 |
|
Atorvastatin |
Approved |
Phase 3 |
|
134523-00-5 |
60823 |
Synonyms:
(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid
(3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid
(betaR,deltaR)-2-(p-Fluorophenyl)-beta,delta-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-1-heptanoic acid
(R-(R*,r*))-2-(4-fluorophenyl)-b,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-b,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
(R-(R*,r*))-2-(4-fluorophenyl)-b,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-b,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
(R-(R*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
(R-(R*,R*))-2-(4-Fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
(R-(R*,r*))-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
134523-00-5
134523-03-8
7-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]- 3,5-DIHYDROXY-HEPTANOIC ACID
7-[2-(4-fluoro-PHENYL)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-3,5-dihydroxy-heptanoate
7-[2-(4-fluoro-PHENYL)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-3,5-dihydroxy-heptanoIC ACID
AC-15611
AC1L1TZT
AC1Q1OZQ
AKOS000281127
Anhydrous, atorvastatin calcium
Atogal
Atorlip
Atorpic
atorvastatin
Atorvastatin
Atorvastatin (INN)
Atorvastatin [INN:BAN]
Atorvastatin acid
Atorvastatin calcium
Atorvastatin calcium anhydrous
Atorvastatin calcium hydrate
Atorvastatin calcium trihydrate
Atorvastatin, calcium salt
atorvastatina
Atorvastatina
atorvastatine
Atorvastatine
atorvastatinium
atorvastatinum
Atorvastatinum
atrovastin
BIDD:GT0336
C06834
C33H35FN2O5
|
Calcium anhydrous, atorvastatin
Calcium hydrate, atorvastatin
Calcium salt atorvastatin
Calcium trihydrate, atorvastatin
Calcium, atorvastatin
Cardyl
CCRIS 7159
CHEBI:39548
CHEMBL1487
CI 981
CID60823
D07474
DB01076
Faboxim
Hipolixan
HSDB 7039
Hydrate, atorvastatin calcium
Lipitor
Lipitor (TN)
Lipitor(TM)
Lipotropic
Lipovastatinklonal
Liprimar
Liptonorm
Lowden
LS-136975
MolPort-000-883-773
NCGC00159458-02
nchembio.301-comp8
Normalip
Sincol
Sortis
Sortis (TN)
Sotis
Torvacard
Torvast
Totalip
Tozalip
Trihydrate, atorvastatin calcium
Tulip
UNII-A0JWA85V8F
Vastina
Xanator
Xarator
Xavator
Zurinel
|
|
31 |
|
Cysteine |
Approved, Nutraceutical |
Phase 3 |
|
52-90-4 |
5862 |
Synonyms:
(+)-2-amino-3-Mercaptopropionic acid
(2R)-2-amino-3-Mercaptopropanoate
(2R)-2-amino-3-mercaptopropanoic acid
(2R)-2-amino-3-Mercaptopropanoic acid
(2R)-2-amino-3-Sulfanylpropanoate
(2R)-2-amino-3-sulfanylpropanoic acid
(2R)-2-amino-3-Sulfanylpropanoic acid
(2R)-2-amino-3-Sulphanylpropanoate
(2R)-2-amino-3-Sulphanylpropanoic acid
(R)-(+)-Cysteine
(R)-2-amino-3-mercapto-Propanoate
(R)-2-amino-3-Mercaptopropanoate
(R)-2-amino-3-mercapto-Propanoic acid
(R)-2-amino-3-Mercaptopropanoic acid
(R)-2-Amino-3-mercaptopropanoic acid
(R)-Cysteine
2-amino-3-Mercaptopropanoate
2-amino-3-Mercaptopropanoic acid
2-amino-3-Mercaptopropionate
2-amino-3-Mercaptopropionic acid
3-mercapto-L-Alanine
Acetylcysteine
alpha-amino-beta-Thiolpropionic acid
beta-Mercaptoalanine
b-Mercaptoalanine
C
Carbocysteine
Cisteina
|
Cisteinum
Cys
Cystein
Cysteine
CYSTEINE
Cysteine hydrochloride
Cysteinum
e 920
e920
e-920
Free Cysteine
FREE cysteine
Half cystine
Half-cystine
L Cysteine
L-(+)-Cysteine
L-2-amino-3-Mercaptopropanoate
L-2-amino-3-Mercaptopropanoic acid
L-2-amino-3-Mercaptopropionate
L-2-amino-3-Mercaptopropionic acid
L-2-Amino-3-mercaptopropionic acid
L-Cys
L-Cystein
L-Zystein
Polycysteine
Thioserine
Zinc cysteinate
|
|
32 |
|
Sodium Channel Blockers |
|
Phase 3 |
|
|
|
33 |
|
Anti-Arrhythmia Agents |
|
Phase 3 |
|
|
|
34 |
|
Diuretics, Potassium Sparing |
|
Phase 3 |
|
|
|
35 |
|
Anesthetics, Local |
|
Phase 3 |
|
|
|
36 |
|
Chelating Agents |
|
Phase 3 |
|
|
|
37 |
|
Iron Chelating Agents |
|
Phase 3 |
|
|
|
38 |
|
Anti-Infective Agents |
|
Phase 3 |
|
|
|
39 |
|
Antiparasitic Agents |
|
Phase 3 |
|
|
|
40 |
|
Antiprotozoal Agents |
|
Phase 3 |
|
|
|
41 |
|
Antirheumatic Agents |
|
Phase 3 |
|
|
|
42 |
|
Antimalarials |
|
Phase 3 |
|
|
|
43 |
|
Anti-Bacterial Agents |
|
Phase 3 |
|
|
|
44 |
|
Hypolipidemic Agents |
|
Phase 3 |
|
|
|
45 |
|
Lipid Regulating Agents |
|
Phase 3 |
|
|
|
46 |
|
carnitine |
|
Phase 3 |
|
|
|
47 |
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors |
|
Phase 3 |
|
|
|
48 |
|
Anticholesteremic Agents |
|
Phase 3 |
|
|
|
49 |
|
Hypoglycemic Agents |
|
Phase 3 |
|
|
|
50 |
|
Ledipasvir |
Approved |
Phase 2 |
|
1256388-51-8 |
67505836 |
Synonyms:
|
Interventional clinical trials:
(show top 50)
(show all 63)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Possible Role of Chloroquine in Conjunction to Prednisone to Induce a Complete Remission in the Treatment of Autoimmune Hepatitis: a Randomized Trial |
Completed |
NCT02463331 |
Phase 4 |
Chloroquine diphosphate;prednisone;azathioprine |
2 |
DOUBLE-BLIND RANDOMIZED CLINICAL TRIAL WITH CHLOROQUINE VERSUS PLACEBO FOR MAINTENANCE OF REMISSION OF AUTOIMMUNE HEPATITIS |
Completed |
NCT01980745 |
Phase 4 |
Chloroquine diphosphate 250mg;Placebo |
3 |
EFFICACY OF KETAMINE-PROPOFOL COMBINATION FOR SHORT SURGICAL PROCEDURES |
Completed |
NCT01651988 |
Phase 4 |
Ketamina-Propofol Combination |
4 |
Effect of Continuous Intravenous Lidocaine on Early Rehabilitation in Bariatric Surgery. A Randomized Double Blind Controlled Study |
Unknown status |
NCT03211455 |
Phase 3 |
Lidocaine;isotonic saline |
5 |
Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda |
Completed |
NCT00599326 |
Phase 3 |
Deferasirox |
6 |
Sorbent Therapy of the Cutaneous Porphyrias |
Completed |
NCT01422915 |
Phase 2, Phase 3 |
Colestipol |
7 |
A Multi-centre, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial, Investigating the Efficacy and Safety of Porphozym (Recombinant Human Porphobilinogen Deaminase) in the Treatment of Acute Attacks in AIP |
Completed |
NCT00418795 |
Phase 2, Phase 3 |
recombinant human porphobilinogen deaminase (Porphozym) |
8 |
Phase III Study of L-Cysteine in Patients With Erythropoietic Protoporphyria |
Completed |
NCT00004940 |
Phase 3 |
cysteine hydrochloride |
9 |
Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care Due to Coronavirus Disease 2019 (COVID-19)- Randomised Controlled Trial |
Recruiting |
NCT04339816 |
Phase 3 |
Azithromycin;Hydroxychloroquine;Placebo |
10 |
ENVISION: A Phase 3 Randomized, Double-blind, Placebo-Controlled Multicenter Study With an Open-label Extension to Evaluate the Efficacy and Safety of Givosiran in Patients With Acute Hepatic Porphyrias |
Active, not recruiting |
NCT03338816 |
Phase 3 |
Givosiran;Placebo |
11 |
Estudio clínico Fase III Para Evaluar la Eficacia terapéutica en Pacientes Mexicanos Con Dislipidemia Mediante el Uso vía Oral de L-Carnitina + Atorvastatina Comparado Con Atorvastatina |
Active, not recruiting |
NCT03696940 |
Phase 3 |
L-Carnitine 500Mg Oral Tablet + Atorvastatin 10 mg;Atorvastatin 10mg |
12 |
The Synergistic Effect of Hypoglycemic Index Diet on Refractory Schizophrenia |
Enrolling by invitation |
NCT04302636 |
Phase 3 |
|
13 |
A Phase II, Open Label Clinical Trial Exploring the Safety and the Efficacy of Oral Deferasirox in Patients Newly Diagnosed With Porphyria Cutanea Tarda (PCT) and Non-transfusion Iron Overload |
Unknown status |
NCT01284946 |
Phase 2 |
Exjade |
14 |
Phase II Study of Heme Arginate in Patients Planned for Cardiac Surgery |
Unknown status |
NCT02142699 |
Phase 2 |
Heme arginate |
15 |
Studies in Porphyria III: Heme and Tin Mesoporphyrin in Acute Porphyrias |
Completed |
NCT00004396 |
Phase 2 |
heme arginate;tin mesoporphyrin |
16 |
Phase I/II Study of Heme Arginate and Tin Mesoporphyrin for Acute Porphyria |
Completed |
NCT00004789 |
Phase 1, Phase 2 |
heme arginate;tin mesoporphyrin |
17 |
A Pilot Study of Hemin Therapy for Gastroparesis |
Completed |
NCT01206582 |
Phase 2 |
|
18 |
A Safety and Efficacy Study to Evaluate Intravenous Heme Arginate Infusion in Patients With an Acute Coronary Syndrome Without ST-elevation (NSTEMI) |
Completed |
NCT00483587 |
Phase 1, Phase 2 |
Heme arginate |
19 |
Safety and Efficacy of Panhematin™ for Prevention of Acute Attacks of Porphyria |
Recruiting |
NCT02922413 |
Phase 2 |
|
20 |
A Prospective Comparison of Low Dose Hydroxychloroquine and Phlebotomy in the Treatment of Porphyria Cutanea Tarda. IRB 02-435 |
Recruiting |
NCT01573754 |
Phase 2 |
Hydroxychloroquine |
21 |
A Multicenter, Open-label Extension Study to Evaluate the Long-term Safety and Clinical Activity of Subcutaneously Administered ALN-AS1 in Patients With Acute Intermittent Porphyria Who Have Completed a Previous Clinical Study With ALN-AS1 |
Active, not recruiting |
NCT02949830 |
Phase 1, Phase 2 |
givosiran (ALN-AS1) |
22 |
A Double-blind, Randomized, Placebo-controlled, Parallel Group Trial on the Efficacy and Safety of PanhematinTM in the Treatment of Acute Attacks of Porphyria |
Active, not recruiting |
NCT02180412 |
Phase 2 |
|
23 |
Newer Direct-Acting Anti-Viral Agents as Sole Therapy of Porphyria Cutanea Tarda in Subjects With Chronic Hepatitis C |
Active, not recruiting |
NCT03118674 |
Phase 2 |
Harvoni |
24 |
A Phase 2, Open-Label, Multiple-Dose Study Investigating the Efficacy and Safety of Panhematin in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome |
Terminated |
NCT00467610 |
Phase 2 |
Panhematin |
25 |
A Drug-Drug Interaction Study to Investigate the Effect of Givosiran on the Pharmacokinetics (PK) of Midazolam, Caffeine, Losartan, Omeprazole, and Dextromethorphan in Patients With Acute Intermittent Porphyria (AIP) Who Are Asymptomatic High Excreters (ASHE) |
Completed |
NCT03505853 |
Phase 1 |
Givosiran;5-probe cocktail |
26 |
A Phase 1, Single-ascending Dose, Multiple-ascending Dose, and Multi-dose Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered ALN AS1 in Patients With Acute Intermittent Porphyria (AIP) |
Completed |
NCT02452372 |
Phase 1 |
givosiran (ALN-AS1);Sterile Normal Saline (0.9% NaCl) |
27 |
Phase I Study of Tin Mesoporphyrin in Patients on Long Term Heme Therapy for Prevention of Acute Attacks of Porphyria |
Completed |
NCT00004397 |
Phase 1 |
heme arginate;tin mesoporphyrin |
28 |
Phase I Study of Heme Arginate With or Without Tin Mesoporphyrin in Patients With Acute Attacks of Porphyria |
Completed |
NCT00004398 |
Phase 1 |
heme arginate;tin mesoporphyrin |
29 |
Phase I, Multicentre, Open Label, Single Dose, Dose-ranging Clinical Trial to Investigate the Safety and Tolerability of a Gene Therapy rAAV2/5-PBGD for the Treatment of Acute Intermittent Porphyria |
Completed |
NCT02082860 |
Phase 1 |
|
30 |
A Single Center, Single Dose, Open-Label, Two-Period Replicate Pilot Study to Investigate Intra-subject Variability in the Bioavailability of a Formulation Containing Chlorpromazine Hydrochloride (25 mg Sugar Coated Tablets) in at Least 16 Healthy Males and Females Under Fasting Conditions |
Completed |
NCT02943213 |
Phase 1 |
Chlorpromazine Hydrochloride |
31 |
Effect of Hemin on Heme-Oxygenase-1 Activity in Healthy Subjects |
Completed |
NCT00882804 |
Phase 1 |
Hemin infusion;placebo infusion |
32 |
Efficacy of Based MRI Contrast Media Against Covid-19 |
Not yet recruiting |
NCT04371822 |
Phase 1 |
SnPP Protoporphyrin plus Sunlight exposure;SnPP Protoporphyrin plus Sunlight exposure;SnPP Protoporphyrin plus Sunlight exposure;Sulfonatoporphyrin(TPPS) plus Sunlight exposure. |
33 |
PentoxIfylline and Tocopherol for the Treatment of Post-radiotherapy Fibrosis in Head and Neck Cancer Patients: a Feasibility Study |
Not yet recruiting |
NCT03723291 |
Phase 1 |
|
34 |
Studies in Porphyria I: Characterization of Enzyme Defects |
Unknown status |
NCT00004331 |
|
|
35 |
Pattern of Skin Manifestations in Chronic Hepatitis c Virus Patients Before and After Direct Acting Anti Viral Drugs: Prospective Controlled Clinical Trial |
Unknown status |
NCT03170076 |
|
|
36 |
The Effects of Visible Light on the Skin After Administration of Oral Polypodium Leucotomos |
Unknown status |
NCT02904798 |
|
Polypodium Leucotomos |
37 |
Randomized Controlled Study of Off-Label Use of Ribavirin in Management of Mucocutaneous Extrahepatic Manifestations of HCV Infection |
Unknown status |
NCT02261662 |
|
Ribavirin;Betamethasone |
38 |
Is Outpatient PDD Guided Laser Mediated Destruction of Bladder Tumors (LMD-BT) as Good as Conventional Inpatient PDD Guided Transurethral Tumor Resection in Patients With Low Grade Non-invasive (Ta) Bladder Tumors? |
Unknown status |
NCT02886026 |
|
|
39 |
Chronic Hepatitis C in Chronic Hemodialysis Recipients - An Observational Study |
Unknown status |
NCT03461250 |
|
|
40 |
“Factors Associated With Porphyria Cutanea Tarda in Patients Infected With Hepatitis C Virus” |
Completed |
NCT00213772 |
|
|
41 |
Studies in Porphyria IV: Gonadotropin-Releasing Hormone (GnRH) Analogues for Prevention of Cyclic Attacks |
Completed |
NCT00004330 |
|
luteinizing hormone-releasing factor |
42 |
Clinical Diagnosis of Acute Porphyria |
Completed |
NCT01568554 |
|
|
43 |
Study of Nutritional Factors in Porphyria |
Completed |
NCT00004788 |
|
|
44 |
Evidence-based Assessment of Medication Sensitivity in Acute Hepatic Porphyria |
Completed |
NCT03906214 |
|
|
45 |
Study of the Pathogenesis of Porphyria Cutanea Tarda |
Completed |
NCT00005103 |
|
|
46 |
Erythropoietic Protoporphyrias: Studies of the Natural History, Genotype-Phenotype Correlations, and Psychosocial Impact |
Completed |
NCT01688895 |
|
|
47 |
Observational Study of Acute Intermittent Porphyria Patients |
Completed |
NCT02076763 |
|
|
48 |
Diagnostic and Screening Study of Genetic Disorders |
Completed |
NCT00006057 |
|
|
49 |
Study of Cysteine Hydrochloride for Erythropoietic Protoporphyria |
Completed |
NCT00004831 |
|
cysteine hydrochloride |
50 |
Effect of Oral Iron Therapy on Erythrocyte Protoporphyrin Levels in the Erythropoietic Protoporphyrias |
Completed |
NCT02979249 |
|
Oral Iron |
Cochrane evidence based reviews: porphyrias
|